Moleculin Biotech (NASDAQ:MBRX) Cut to Hold at Maxim Group

Moleculin Biotech (NASDAQ:MBRX) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Briefing.com Automated Import reports.

Separately, StockNews.com assumed coverage on shares of Moleculin Biotech in a report on Sunday. They issued a “sell” rating on the stock.

Moleculin Biotech Price Performance

NASDAQ MBRX opened at $0.51 on Wednesday. The stock’s fifty day moving average price is $1.80 and its 200 day moving average price is $2.28. Moleculin Biotech has a 1 year low of $0.50 and a 1 year high of $10.35.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.